- Home
- CIO vs MRSN Comparison
CIO vs MRSN Comparison
Compare CIO & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIO
- MRSN
- Stock Information
- Founded
- CIO 2013
- MRSN 2001
- Country
- CIO Canada
- MRSN United States
- Employees
- CIO N/A
- MRSN N/A
- Industry
- CIO Real Estate Investment Trusts
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CIO Real Estate
- MRSN Health Care
- Exchange
- CIO Nasdaq
- MRSN Nasdaq
- Market Cap
- CIO 230.9M
- MRSN 230.0M
- IPO Year
- CIO 2014
- MRSN 2017
- Fundamental
- Price
- CIO $4.88
- MRSN $2.21
- Analyst Decision
- CIO
- MRSN Buy
- Analyst Count
- CIO 0
- MRSN 6
- Target Price
- CIO N/A
- MRSN $6.00
- AVG Volume (30 Days)
- CIO 199.8K
- MRSN 1.1M
- Earning Date
- CIO 10-31-2024
- MRSN 11-13-2024
- Dividend Yield
- CIO 8.18%
- MRSN N/A
- EPS Growth
- CIO N/A
- MRSN N/A
- EPS
- CIO N/A
- MRSN N/A
- Revenue
- CIO $173,528,000.00
- MRSN $34,837,000.00
- Revenue This Year
- CIO N/A
- MRSN N/A
- Revenue Next Year
- CIO $0.25
- MRSN $7.15
- P/E Ratio
- CIO N/A
- MRSN N/A
- Revenue Growth
- CIO N/A
- MRSN N/A
- 52 Week Low
- CIO $4.02
- MRSN $1.22
- 52 Week High
- CIO $6.71
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- CIO 32.25
- MRSN 51.26
- Support Level
- CIO $5.01
- MRSN $2.12
- Resistance Level
- CIO $5.43
- MRSN $2.83
- Average True Range (ATR)
- CIO 0.21
- MRSN 0.24
- MACD
- CIO -0.04
- MRSN 0.03
- Stochastic Oscillator
- CIO 7.38
- MRSN 39.81
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. The company owns office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.